Celgene Names Alles as CEO; Hugin to Be Executive ChairmanBy
Jacqualyn Fouse to take over as chief operating officer
Drugmaker climbed to about $80 billion valuation under Hugin
Celgene Corp. promoted Chief Operating Officer Mark Alles to chief executive officer, with Bob Hugin remaining at the drugmaker as executive chairman after almost six years as CEO.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.